Loading articles...

In the early 19th century, Dr. William Coley pioneered a novel approach to cancer treatment with what became known as Coley's toxins. He believed that injecting killed bacteria into cancer patients could stimulate the immune system and cause tumors to shrink. Although his method faced skepticism and eventually fell out of favor, Coley's groundbreaking work laid the foundation for the development of modern cancer immunotherapy.
Coley's interest in bacterial immunotherapy was sparked by historical reports of cancer regression following severe infections. In the 18th and 19th centuries, physicians observed that some patients experienced tumor shrinkage after contracting bacterial illnesses. Motivated by the tragic death of a young cancer patient, Elizabeth Dashiell, Coley began researching these phenomena. He discovered several cases where cancer patients who developed bacterial infections underwent spontaneous tumor regression. Building on these findings, Coley created a bacterial cocktail containing Streptococcus pyogenes and Serratia marcescens, which he used to treat cancer patients—achieving mixed but occasionally remarkable results.
Despite showing promise in some cases, Coley's toxins were met with skepticism due to the absence of standardized clinical trials and consistent outcomes. By the mid-20th century, the rise of chemotherapy and radiation therapy overshadowed Coley's approach, leading to a decline in its use. Additionally, regulatory changes in the 1960s further restricted access to his bacterial treatments. Still, Coley's groundbreaking work laid the foundation for modern cancer immunotherapy. Today, targeted immunotherapies, such as checkpoint inhibitors and CAR-T cell therapy, reflect the same principle of harnessing the immune system to fight cancer. Ongoing research into bacterial-based treatments continues to validate Coley's early insights—revealing just how far ahead of his time he truly was.
Although Coley's toxins are no longer used, their impact on cancer treatment remains significant. His innovative approach demonstrated the potential of the immune system in fighting cancer, paving the way for today's immunotherapies. While his treatment was not widely accepted in his time, it helped inspire modern breakthroughs that continue to improve cancer care.

Explore how eosinophils, once known for their role in allergies and parasites, are now influencing cancer outcomes—sometimes acting as defenders, other times as accomplices in tumor progression.

Stereotactic Radiosurgery (SRS) is a non-invasive cancer treatment that uses precise, high-dose radiation beams to target tumors, especially in the brain, spine, and lungs. It delivers focused radiation with minimal damage to healthy tissue, often in just 1–5 sessions. SRS is ideal for small, well-defined tumors and offers quick recovery, though it's not suitable for larger or widespread cancers.

Understand how modern immunotherapy harnesses the body's own immune system to fight cancer, revolutionizing treatment approaches and outcomes.